Scam report Scam Alerts

NatuZem FDA Warning: Arthritis Claims, Unapproved Drugs and Buyer Risks

By Lapain Epuran11 min read

NatuZem’s catalog brings joint-care products, sexual-performance products, and familiar botanical ingredients into the same shopping experience. The names on those packages deserve more than a quick glance.

A treatment promise changes the questions a buyer should ask. With this retailer, the distinction between the advertised benefit and the evidence behind it is especially important.

NatuZem storefront showing its health and sexuality collections and a promotional tablet box, not the FDA-named Testiton vials

Overview

The FDA warning concerns three disease-treatment offers

The NatuZem FDA warning dated October 26, 2026 follows a September website review. FDA identified three products as unapproved new drugs under United States law.

  • Testitón Extra Strong vials were promoted with claims about ejaculation and erections.
  • Reumofan Plus was promoted for arthritis and other conditions, including bone cancer.
  • Artrifan King was promoted with cartilage claims and claimed protection against bone cancer.

These examples come from the FDA’s dated review. They should not be presented as a verbatim account of every product page currently displayed.

Current product presentation does not settle the warning

The current listings present the named products with ingredient descriptions, prices, and quantity controls. Those familiar shopping details leave the underlying treatment claims unresolved.

The FDA’s exact historical sentences were absent from the visible main-product text examined. However, the displayed Reumofan box image still carried a bone-cancer prevention claim.

The approval issue matters without new laboratory testing

FDA expressly says it had not tested the cited variations from NatuZem’s inventory. Older laboratory findings involving similarly named products cannot be assigned to this stock.

Do not buy these named products as treatments for arthritis, bone cancer, or sexual dysfunction. Seek appropriate medical care instead of relying on the disputed promises.

What the NatuZem FDA Warning Actually Establishes

The central finding concerns intended use and missing drug approvals. A product can be marketed as a drug through its treatment claims, regardless of reassuring presentation.

FDA explains that the three named products were not generally recognized as safe and effective for the uses suggested in their labeling.

The agency also says no approved applications were in effect for those products. It therefore describes their introduction into United States interstate commerce as unlawful.

This is more specific than saying every natural product requires FDA approval. The letter addresses these products and the medical uses promoted for them.

The FDA’s explanation of unapproved drugs distinguishes approval from simple drug listing. An identification number or listing does not establish approved safety and effectiveness.

A purchase button offers no medical reassurance. The ability to advertise a product says nothing about whether its promised treatment has been approved.

A warning letter gives its recipient an opportunity to respond and correct violations. It is not a criminal conviction or proof that every catalog item is fraudulent.

FDA gave NatuZem fifteen business days after receiving the letter to respond. That regulatory deadline is not your return period and does not promise reimbursement.

Separate the Three Products Before Comparing Claims

The complete name and dosage form help identify what FDA discussed. A similarly named tablet, a premium version, and a vial presentation are not automatically interchangeable.

Product in the letter Claim FDA documented during its September review
Testitón Extra Strong vials FDA cited claims about reducing premature ejaculation and improving erections through circulation.
Reumofan Plus FDA cited treatment language encompassing arthritis, osteoarthritis, osteoporosis, and bone cancer.
Artrifan King FDA cited cartilage regeneration, improved mobility, and additional protection against bone cancer.

The current Testitón product view described ten vials and separately linked a 100-tablet presentation. The promotional tablet box on the homepage is not the vial product.

Current Reumofan Plus and Artrifan King views each described 30 tablets. Those catalog descriptions identify the offers, not the chemical contents of a delivered package.

Keep the version shown on your receipt and the actual package together. A generic brand search can otherwise connect your purchase to the wrong warning.

For Reumofan, also distinguish the standard listing from the separately offered premium version. A matching name fragment cannot establish the same formulation or manufacturer.

MalwareTips’ separate Demograss Premier investigation covers a different product and a phenolphthalein finding. That result is not evidence about these three products.

How the Current Listings Compare With FDA’s Review

The FDA letter records specific language from September, while today’s product descriptions emphasize ingredients, package contents, and customer feedback. The distinction matters when judging a claimed correction.

The historical disease-treatment sentences were absent from the visible main descriptions examined. Removing those particular sentences would still leave the rest of the sales presentation to consider.

But product photographs are part of what shoppers see. The Reumofan image displayed wording claiming prevention of cancer in the bones, despite the changed surrounding text.

The photograph cannot establish what arrives in your order. For someone shopping now, however, its cancer-prevention promise remains part of the offer.

The Artrifan page also displayed a customer-review summary describing joint-pain improvement. Customer stories do not demonstrate cartilage regeneration or cancer prevention in a clinical trial.

The Testitón ingredient description named yohimbine and methyltestosterone alongside botanical names. These are seller declarations, not independently measured findings about the vials.

The National Cancer Institute describes methyltestosterone as a synthetic androgen. Its appearance in ingredient text should not be mistaken for a routine herbal description.

No quantity of that substance was independently established, and no treatment schedule is endorsed here. Bring the declaration and actual package to a qualified clinician.

Some product panels stated availability only for Mexico. That statement does not establish how the United States marketing concerns were resolved or determine every checkout’s eligibility.

Why Older Hidden-Drug Alerts Need Careful Handling

FDA’s letter cites earlier investigations of similarly named Reumofan, Artrifan, and other products. Those investigations explain the agency’s additional safety concern.

They do not erase the letter’s explicit limit: FDA had not sampled these variations from NatuZem’s inventory. Naming an older contaminant as a current finding would be misleading.

The historical Reumofan guidance also explains why users need professional advice. Undeclared medicines in previously tested products raised interaction and withdrawal concerns.

Do not turn that history into a homemade taper, a diagnosis, or instructions to change prescribed treatment. A clinician needs to assess the product actually taken.

The absence of a new inventory test is not independent proof of safety either. It leaves a contents question unanswered while the documented approval issue remains.

Arthritis Relief and Bone-Cancer Claims Are Different Medical Questions

Joint discomfort can make a broad promise attractive, but arthritis and bone cancer are not interchangeable diagnoses. Neither should be diagnosed from a product advertisement.

The National Institute of Arthritis and Musculoskeletal and Skin Diseases explains that osteoarthritis assessment considers medical history, examination, and sometimes imaging or other tests.

Its treatment discussion focuses on individualized goals such as pain reduction and better joint function. It includes supervised activity, appropriate supports, medicines, and sometimes surgery.

That is not a prescription to select those options yourself. It explains why a qualified assessment is more useful than an undifferentiated promise about joint repair.

Feeling less pain after taking something does not establish that cartilage regenerated. It also does not show that an underlying disease stopped progressing.

The National Cancer Institute’s bone-cancer guidance distinguishes cancers beginning in bone from cancers spreading there. Diagnosis and treatment depend on the actual condition.

A claim to prevent cancer in the bones skips those distinctions. A customer testimonial, attractive carton, or herbal ingredient list cannot supply the missing clinical evidence.

Persistent or unusual bone pain and swelling deserve medical evaluation. They may have several causes, so neither assume cancer nor rely on a supplement to exclude it.

If cancer has already been diagnosed, bring any proposed product to the oncology team. Do not let a retail promise displace the treatment plan they supervise.

Sexual-Performance Claims Also Need a Real Care Path

The Testitón examples in the letter address ejaculation and erections. Those concerns do not automatically share one cause or one appropriate treatment.

NIDDK’s erectile-dysfunction guidance recommends evaluating underlying causes when possible. Existing medicines, other health conditions, and psychological factors can affect the approach.

It specifically advises professional discussion before ordering erectile-dysfunction medicines online or using complementary products. Interactions with other medicines can create additional problems.

An ingredient declaration containing a hormone-related drug name makes that discussion particularly important. It does not demonstrate that these vials are approved or suitable for you.

Describe the concern directly to a healthcare professional rather than experimenting with a seller’s instructions. Bring your medicine list so that discussion includes possible interactions.

The Retailer, Addresses, and Return Route

NatuZem is the retailer addressed by FDA

The warning identifies natuzem.com and two published store email addresses. The current terms of service likewise name NatuZem as the operator.

Those terms identify Shopify as the commerce platform. That relationship does not make the platform the manufacturer, medical reviewer, or issuer of a product approval.

The two Mexico addresses have different stated roles

FDA addressed its letter to 201 General Guadalupe Victoria in Aguascalientes. NatuZem’s refund page directs returns to Gorostiza 114 in the same city.

These are a regulatory-recipient address and a published return destination. Their difference does not establish that either location is fake or that purchases were never shipped.

Product branding does not independently identify every manufacturer

Current product titles and packaging contain brand names, but a catalog photograph is not an independently verified manufacturing record. NatuZem’s retail role should remain distinct.

The vial listing uses The King branding, while the Artrifan title names Omega Nutrition. The Artrifan package photograph also displays Golden branding.

These names help identify what the retailer advertises, but they do not independently resolve who produced a particular lot. Your actual package can supply more specific identifiers.

For an existing purchase, retain the producer and distributor details actually printed on the package. Do not replace them with the name of another similarly branded product.

The ordinary return policy has important limits

The current refund policy starts its ordinary 30-day window at purchase, not delivery. It requires unused goods, original packaging, and proof of purchase.

It also lists exclusions for sale items and certain health or personal-care goods. Those provisions leave important questions for someone who already opened an ingestible product.

Ask how the policy applies to your specific warning-related request. No refund conversation was tested, so neither guaranteed reimbursement nor an automatic refusal should be assumed.

The policy assigns ordinary return costs to the buyer and describes shipping charges as nonrefundable. Obtain clear instructions before sending evidence-bearing packaging back to Mexico.

NatuZem refund policy displaying its purchase-based 30-day window, unused condition and health-product exclusions

Discounts Do Not Establish Your Purchase or Renewal Terms

The Mexican-peso listings showed Testitón vials at MX$150, Reumofan Plus at MX$220, and Artrifan King at MX$249. These were product prices before checkout charges.

They were not completed order totals or verified currency conversions for a United States buyer. Final shipping, payment terms, and transaction eligibility were not established.

The quantity fields showed one alongside larger-purchase discounts. A highlighted bulk tier did not establish that fourteen packages had been accepted or purchased.

The Testitón offer reduced its displayed unit price to MX$97.50 for fourteen or more boxes. That comparison concerns multiple boxes, not fourteen vials within one box.

Bundle and refill warning

One Testitón vial box was displayed at MX$150 with quantity one and larger-quantity discounts. A highlighted discount is not confirmation of your accepted package.

No final checkout or renewal consent was inspected. A purchase suggestion, discount tier, or newsletter signup does not establish recurring-payment enrollment.

Avoid buying these products as disease treatments. For an existing order, check the actual receipt and any separate authorization before challenging a specific charge.

What to Do If You Ordered a Named Product

  1. Match the warning to your actual purchase. Compare the complete name, vial or tablet presentation, package count, producer details, and lot markings with your receipt.

    Preserve the original packaging and any remaining product. That information helps a clinician assess exposure without guessing from a similar brand name.

  2. Take the medical claim to a professional. Explain whether the product was purchased for joint symptoms, sexual function, or a diagnosed condition.

    Share what you have already taken and which prescribed medicines you use. Ask promptly about appropriate care rather than making independent treatment changes.

  3. Seek urgent help for a severe reaction. Serious symptoms require medical attention before a seller’s reply, a return decision, or an online discussion.

    Bring the package information when practical, without delaying care. Do not let uncertainty about the ingredient list prevent you from describing what happened.

  4. Send the retailer a focused written request. Cite reference 737558 and identify your product, purchase date, and requested cancellation or refund.

    Ask whether any unopened-product condition or sale exclusion is being applied, and request the answer in writing before arranging a return.

  5. Keep health reporting separate from payment recovery. Report a suspected adverse event through FDA’s medical-product safety reporting route, describing facts rather than declaring an unproved contaminant.

    If the commercial dispute remains unresolved, promptly ask your payment provider about its applicable process. There is no universal deadline or guaranteed recovery for every payment.

Frequently Asked Questions

Which NatuZem products are named in this FDA warning?

The unapproved-new-drug findings name Testitón Extra Strong vials, Reumofan Plus, and Artrifan King. Other products appear in the letter’s separate discussion of earlier safety alerts.

Did FDA test NatuZem’s inventory for hidden medicines?

The letter expressly says it had not tested the cited inventory variations. Historical findings for similar names must not be presented as laboratory results for this stock.

Are the FDA’s old claims still visible online?

The exact historical sentences were absent from the current visible main text examined. However, the displayed Reumofan package image still made a bone-cancer prevention claim.

Does a new product description mean FDA cleared the seller?

A changed page does not establish regulatory clearance or address every issue. A complete corrective response and its outcome were not independently verified.

Does the largest discount automatically order a large bundle?

The observed quantity remained one despite highlighted bulk pricing. Only your actual accepted order and payment records can establish which package you purchased.

Can I get a refund after opening the package?

The ordinary policy requires unused goods and contains exclusions. Ask NatuZem to address your particular FDA-warning request, while protecting any separate payment-provider options.

The Bottom Line

The NatuZem FDA warning concerns unsupported disease-treatment marketing and missing drug approvals. It does not establish a new laboratory finding for every package on the site.

Do not buy the named products as arthritis, bone-cancer, or sexual-dysfunction treatments. Neither a changed description nor a quantity discount supplies the medical evidence you need.

Already purchased one of these products? Bring its actual details to a healthcare professional, then pursue the retailer’s written response and appropriate payment options.

Make your next click a safer one.

Spotting a scam is a good start. These tools can add protection when you browse, open messages, or download software.

Affiliate links We may earn a commission if you buy through these links, at no extra cost to you. How we’re funded

MalwarebytesSCAM & MALWARE PROTECTION

Scam awareness. Malware protection.

Malwarebytes combines device protection with tools for checking suspicious messages and links, so you have more information before you act.

  • Scam Guard for suspicious messages
  • Real-time malware protection with Premium
Explore MalwarebytesExplore features on the official website
AdGuardAD & TRACKER BLOCKING

Less clutter. More control.

AdGuard filters intrusive ads and trackers, helping reduce unwanted interruptions and giving you more control over your browsing.

  • Blocks intrusive ads and pop-ups
  • Filters trackers while you browse
Explore AdGuardExplore features on the official website

Features vary by device and plan. These tools add protection; they do not guarantee that a website or offer is trustworthy.

Join the discussion

0 comments

Share your experience or ask a question about this article.

Discussion

Start the conversation

Have a question or something useful to share? Add the first comment.

Report a comment

Reports are private and reviewed by a moderator.

Written by

Lapain Epuran

Lapain Epuran investigates product scams, from supplements sold with miracle-cure claims to gadgets pushed through misleading ads. She has more than 10 years of experience in investigations and checks each product's claims, seller and refund terms before giving a verdict.

4,790 articlesWriting since 2024
More from Lapain →

MalwareTips community · since 2010

Stuck on a step? 75,000+ members can help you for free.

Post your question on the forum and our volunteer malware removal experts will walk you through it, step by step.

75K+members
999K+forum messages
100K+forum topics
17+years online

Previous

What to Check When Chrome Asks to Connect a Website to Your USB Device

Next

What Android Actually Keeps When You Archive an App Instead of Removing It

Share